Jazz’ small cell lung cancer therapy wins US green light
The approval gives patients who relapse a new second-line option for the first time in nearly 20 years
Read More
Tag: SCLC
Keytruda misses key lung cancer survival endpoint
The drug significantly improved progression-free survival, but missed its overall survival endpoint.
Read More
Orphan Drug Designation granted for AZ’ Imfinzi
The decision comes hot on the heels of the Phase III CASPIAN trial, which met its primary endpoint.
Read More
Opdivo fails to hit key target in small cell lung cancer study
Bristol-Myers Squibb’s immunotherapy Opdivo did not hit the primary target of a late-stage study testing its efficacy in certain patients with small cell lung cancer.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
